Near-Complete Remission of Glioblastoma in a Patient Treated with an Allogenic Dendritic Cell-Based Vaccine: The Role of Tumor-Specific CD4+T-Cell Cytokine Secretion Pattern in Predicting Response and Recurrence.

Pinho MP., Lepski GA., Rehder R., Chauca-Torres NE., Evangelista GCM., Teixeira SF., Flatow EA., de Oliveira JV., Fogolin CS., Peres N., Arévalo A., Alves V., Barbuto JAM., Bergami-Santos PC.

Immunotherapy has brought hope to the fight against glioblastoma, but its efficacy remains unclear. We present the case of CST, a 25-year-old female patient with a large right-hemisphere glioblastoma treated with a dendritic-tumor cell fusion vaccine. CST showed a near-complete tumor response, with a marked improvement in her functional status and simultaneous increases in tumor-specific CD8+ and CD4+ T cells. Two months before recurrence, the frequency of tumor-specific T cells decreased, while that of IL-17 and CD4+ T cells increased. CST passed away 15 months after enrollment. In this illustrative case, the tumor-specific CD4+ T-cell numbers and phenotype behaved as treatment efficacy biomarkers, highlighting the key role of the latter in glioblastoma immunotherapy.

DOI

10.3390/ijms23105396

Type

Journal article

Publication Date

2022-05-12T00:00:00+00:00

Volume

23

Keywords

CD4+ T cells, cancer treatment, dendritic cells, glioblastoma, immunotherapy, vaccine, CD4-Positive T-Lymphocytes, Cancer Vaccines, Cytokines, Dendritic Cells, Female, Glioblastoma, Humans

Permalink More information Close